title: Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia.
authors.affiliation: West Suffolk Hospital, Bury St Edmund's, UK.
authors.forename: Yin Ling
authors.initials: YL
authors.lastname: Woo
authors.forename: Shuba
authors.initials: S
authors.lastname: Allard
authors.forename: Hannah
authors.initials: H
authors.lastname: Cohen
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Letsky
authors.forename: Michael
authors.initials: M
authors.lastname: de Swiet
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D000990:Antithrombin III / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000139:chemically induced / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000990:Antithrombin III; D001241:Aspirin; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid